Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: Therapeutic RNA interference

Journal of Controlled Release

Volumn 180, Issue 1, 2014, Pages 100-108

  Majumder, Poulami ^a   Bhunia, Sukanya ^a,b   Bhattacharyya, Jayanta ^a   Chaudhuri, Arabinda ^a,b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Antiangiogenic cancer therapy; CDC20siRNA; Cell cycle regulation; In vivo RNAi; Liposomal siRNA delivery

Indexed keywords

CANCER THERAPY; CDC20SIRNA; CELL CYCLE REGULATION; IN-VIVO; SIRNA DELIVERY;

CELL DEATH; CELL PROLIFERATION; ENDOTHELIAL CELLS; LIPOSOMES; MAMMALS; ONCOLOGY; RNA;

TUMORS;

CELL CYCLE PROTEIN; CELL DIVISION CYCLE HOMOLOGUE 20 SMALL INTERFERING RNA; FLUORESCENT DYE; INTEGRIN RECEPTOR; LIPOPEPTIDE; LIPOSOME; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VERY LATE ACTIVATION ANTIGEN 5; CDC20 PROTEIN, MOUSE; CELL CYCLE PROTEIN 20; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CELL CYCLE M PHASE; CELL POPULATION; ENCAPSULATION; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MELANOMA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA INTERFERENCE; TISSUE SECTION; TUMOR MODEL; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; GENE THERAPY; GENETICS; NEOPLASMS; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANIMALS; APOPTOSIS; CDC20 PROTEINS; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC THERAPY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOSOMES; MICE; MICE, INBRED C57BL; NEOPLASMS; PEPTIDES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84896744316     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.02.012     Document Type: Article

References (39)

1. S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001 494 498
2. E. Song et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat. Biotechnol. 23 2005 709 717
3. P. Kumar, H. Wu, J.L. McBride, K.E. Jung, M.H. Kim, and B.L. Davidson et al. Transvascular delivery of small interfering RNA to the central nervous system Nature 448 2007 39 43
4. J.O. McNamara II, E.R. Andrechek, Y. Wang, K.D. Viles, R.E. Rempel, and E. Gilboa et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras Nat. Biotechnol. 24 2006 1005 1015
5. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, and C.A. Alabi et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
6. T.S. Zimmermann, A.C. Lee, A. Akinc, B. Bramlage, D. Bumcrot, and M.N. Fedoruk et al. RNAi-mediated gene silencing in non-human primates Nature 441 2006 111 114
7. B.J. Li, Q. Tang, D. Cheng, C. Qin, F.Y. Xie, and Q. Wei et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque Nat. Med. 11 2005 944 951
8. M. Kortylewski, P. Swiderski, A. Herrmann, L. Wang, C. Kowolik, and M. Kujawski et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses Nat. Biotechnol. 27 2009 925 932
9. H. Poeck, R. Besch, C. Maihoefer, M. Renn, D. Tormo, and S.S. Morskaya et al. 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma Nat. Med. 14 2008 1256 1263
10. A. Fire, S.Q. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
11. N. Jiang, X. Zhang, X. Zheng, D. Chen, K. Siu, H. Wang, T.E. Ichim, D. Quan, V. McAlister, G. Chen, and W.P. Min A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitis PLoS One 7 2012 e44138
12. M. Scherr, K. Battmer, I. Dallmann, A. Ganser, and M. Eder Inhibition of GMCSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model Oligonucleotides 13 2003 353 363
13. Y. Sakurai, H. Hatakeyama, Y. Sato, M. Hyodo, H. Akita, and H. Harashima Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system Mol. Ther. 21 2013 1195 1203
14. G.D. Kenny, N. Kamaly, T.L. Kalber, L.P. Brody, M. Sahuri, E. Shamsaei, A.D. Miller, and J.D. Bell Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualization and therapeutic tumour reduction in vivo J. Control. Release 149 2011 111 116
15. K. Hamada, M. Udea, M. Satoh, N. Inagaki, H. Shimada, and H. Yamada-Okabe Increased expression of the genes for mitotic spindle assembly and chromosome segregation in both lung and pancreatic carcinomas Cancer Gen. Prot. 1 2004 231 240
16. J.M. Kim, H.Y. Sohn, and S.Y. Yoon Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tag expressed in gastric cancer cells Clin. Cancer Res. 11 2005 473 482
17. A. Mukherjee, J. Bhattacharyya, M.V. Sagar, and A. Chaudhuri Liposomally encapsulated CDC20 siRNA inhibits both solid melanoma tumor growth and spontaneous growth of intravenously injected melanoma cells on mouse lung Drug Deliv. Transl. Res. 3 2013 224 234
18. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6 2007 273 286
19. S.M. Weis, and D.A. Cheresh Tumor angiogenesis: molecular pathways and therapeutic targets Nat. Med. 17 2011 1359 1370
20. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 2010 9 22
21. R.O. Hynes Integrins: bidirectional, allosteric signaling machines Cell 110 2002 673 687
22. F.G. Giancotti, and E. Ruoslahti Integrin signaling Science 285 1999 1028 1032
23. J.A. Varner, D.A. Emerson, and R.L. Juliano Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin Mol. Biol. Cell 6 1995 725 740
24. D. Pramanik, B.K. Majeti, G. Mondal, P.P. Karmali, and A. Chaudhuri et al. Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic α5β1 integrin receptor and mouse tumor vasculature J. Med. Chem. 51 2008 7298 7302
25. A. Musacchio, and K.G. Hardwick The spindle checkpoint: structural insights into dynamic signaling Nat. Rev. Mol. Cell Biol. 3 2002 731 741
26. A. Musacchio, and E.D. Salmon The spindle-assembly checkpoint in space and time Nat. Rev. Mol. Cell Biol. 8 2007 379 393
27. C.L. Rieder, and H. Maiato Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint Dev. Cell 7 2004 637 651
28. K.E. Gascoigne, and S.S. Taylor Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs Cancer Cell 14 2008 111 122
29. J.D. Orth, Y. Tang, J. Shi, C.T. Loy, C. Amendt, C. Wilm, F.T. Zenke, and T.J. Mitchison Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate Mol. Cancer Ther. 7 2008 3480 3489
30. D.A. Brito, and C.L. Rieder Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint Curr. Biol. 16 2006 1194 1200
31. S.S. Taylor, and F. McKeon Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage Cell 89 1997 727 735
32. H.J. Shin, K.H. Baek, A.H. Jeon, M.T. Park, S.J. Lee, and C.M.H. Kang et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability Cancer Cell 4 2003 483 497
33. W. Tao, V.J. South, Y. Zhang, and J.P. Davide et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage Cancer Cell 8 2005 49 59
34. C. Swanton, M. Marani, O. Pardo, P.H. Warne, and G. Kelly et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs Cancer Cell 11 2007 498 512
35. M.E. Bekier, R. Fischbach, J. Lee, and W.R. Taylor Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit Mol. Cancer Ther. 8 2009 1646 1654
36. H.C. Huang, J. Shi, J.D. Orth, and T.J. Mitchison Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly Cancer Cell 16 2009 347 358
37. K. Taniguchi, N. Momiyama, M. Ueda, R. Matsuyama, R. Mori, and Y. Fujii et al. Targeting of CDC20 via small interfering RNA causes enhancement of the cytotoxicity of chemoradiation Anticancer Res. 28 2008 1559 1563
38. J.M. Eichhorn, N. Sakurikar, S.E. Alford, R. Chu, and T.C. Chambers Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death Cell Death Dis. 4 2013 e834
39. S.D. Li, Y.C. Chen, M.J. Hackett, and L. Huang Tumor-targeted delivery of siRNA by self-assembled nanoparticles Mol. Ther. 16 2008 163 169g